Lin BioScience Inc.
Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to eva… Read more
Lin BioScience Inc. (6696) - Total Liabilities
Latest total liabilities as of June 2025: NT$139.81 Million TWD
Based on the latest financial reports, Lin BioScience Inc. (6696) has total liabilities worth NT$139.81 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lin BioScience Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how Lin BioScience Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lin BioScience Inc. Competitors by Total Liabilities
The table below lists competitors of Lin BioScience Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Basellandschaftliche Kantonalbank
SW:BLKB
|
Switzerland | CHF33.57 Billion |
|
Pason Systems Inc
OTCQX:PSYTF
|
USA | $108.52 Million |
|
Mavi Giyim Sanayi Ve Ticaret AS
IS:MAVI
|
Turkey | TL11.01 Billion |
|
Ubisoft Entertainment
PINK:UBSFF
|
USA | $2.75 Billion |
|
Anhui Water Resources Development Co Ltd
SHG:600502
|
China | CN¥183.04 Billion |
|
Navigator Co. S/A
LSE:0KLO
|
UK | €1.44 Billion |
|
Zhejiang Zhaolong Interconnect Technology Co. Limited
SHE:300913
|
China | CN¥339.78 Million |
|
Imerys SA
PA:NK
|
France | €3.25 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Lin BioScience Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 41.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lin BioScience Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lin BioScience Inc. (2019–2024)
The table below shows the annual total liabilities of Lin BioScience Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$173.22 Million | +3.27% |
| 2023-12-31 | NT$167.73 Million | +44.53% |
| 2022-12-31 | NT$116.06 Million | -75.32% |
| 2021-12-31 | NT$470.25 Million | +52.25% |
| 2020-12-31 | NT$308.87 Million | +191.48% |
| 2019-12-31 | NT$105.97 Million | -- |